FDA Puts GlaxoSmithKline's (GSK) Avandia TIDE Trial on Partial Clinical Hold (Previously Reported)
- Wall Street falls ahead of inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- Synergy Pharma (SGYP) Trulance (Plecanatide) Approved by FDA
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
The U.S. Food and Drug Administration today informed GlaxoSmithKline (NYSE: GSK), the manufacturer of the diabetes drug Avandia (rosiglitazone), that the postmarketing trial known as TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) has been placed on partial clinical hold.
Under the partial clinical hold no new patients may be enrolled into the trial until further notice from the FDA. Patients already enrolled in the trial will be allowed to continue to participate.
The FDA has instructed GSK to update investigators, institutional review boards (IRBs) and ethics committees involved in the TIDE trial regarding new safety information presented at the joint FDA Advisory Committee meeting held on July 13 and 14, 2010, along with information regarding the deliberations and votes of that meeting.
This information can be used by investigators and IRBs to update existing informed consent information for current trial participants.
The FDA is evaluating available information on Avandia's safety and the discussions of the recent advisory committee meeting. The FDA will update the public on the outcome of its review and its implications for Avandia and the TIDE trial when the review is complete.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leap Presents Biomarker Data from Study of DKN-01 Combo with Paclitaxel in Esophageal Cancer (MCUR)
- W.R. Berkley (WRB) Appoints Mir Mazhar to CPO
- AbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!